Compare · IRD vs NVO
IRD vs NVO
Side-by-side comparison of Opus Genetics Inc. (IRD) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IRD and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.82B, about 492.3x IRD ($373.4M).
- Over the past year, IRD is up 537.8% and NVO is down 34.2% - IRD leads by 572.0 points.
- IRD has been more active in the news (17 items in the past 4 weeks vs 5 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 9 for IRD).
- Company
- Opus Genetics Inc.
- Novo Nordisk A/S
- Price
- $5.23+0.38%
- $41.18+6.93%
- Market cap
- $373.4M
- $183.82B
- 1M return
- +10.22%
- +13.32%
- 1Y return
- +537.80%
- -34.24%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 17
- 5
- Recent ratings
- 9
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest IRD
- Opus Genetics Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation
- SEC Form 144 filed by Opus Genetics Inc.
- SEC Form 144 filed by Opus Genetics Inc.
- SEC Form EFFECT filed by Opus Genetics Inc.
- SEC Form 4 filed by Rodgers Richard J
- SEC Form 4 filed by Manuso James S J
- SEC Form 4 filed by Benton Susan
- SEC Form 4 filed by Gallagher Cam
- SEC Form 4 filed by Graves Adrienne L
- SEC Form 4 filed by Bennett Jean
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S